Tags

Type your tag names separated by a space and hit enter

Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study.
J Eur Acad Dermatol Venereol. 2007 Aug; 21(7):942-50.JE

Abstract

BACKGROUND

The first choice treatment for vitiligo vulgaris is narrow-band UVB (NB-UVB), but no satisfactory treatment exists.

OBJECTIVES

To investigate if Polypodium leucotomos, an antioxidative and immunomodulatory plant extract, improves NB-UVB-induced repigmentation.

METHODS

Fifty patients with vitiligo vulgaris randomly received 250 mg oral P. leucotomos or placebo three times daily, combined with NB-UVB twice weekly for 25-26 weeks.

RESULTS

Repigmentation was higher in the P. leucotomos group vs. placebo in the head and neck area (44% vs. 27%, P = 0.06). Small repigmentation increases (P = n.s.) were observed for the trunk (6% increased repigmentation), extremities (4%), and hands and feet (5%) in the P. leucotomos group vs. placebo. Patients attending more than 80% of required NB-UVB sessions showed increased repigmentation in the head and neck area in the P. leucotomos group vs. placebo (50% vs. 19%, P < 0.002); no significant differences were seen in the other body areas. Patients with skin types 2 and 3 showed more repigmentation in the head and neck area in the P. leucotomos group vs. placebo (47% vs. 21%, P = 0.01), and no significant differences were seen in the other body areas. No conclusions could be drawn on skin types 4 and 5 due to low patient numbers.

CONCLUSION

There is a clear trend towards an increase in repigmentation of vitiligo vulgaris affecting the head and neck area when NB-UVB phototherapy is combined with oral P. leucotomos. This effect may be more pronounced in light skin types.

Authors+Show Affiliations

Netherlands Institute for Pigment Disorders, Department of Dermatology, Academic Medical Center, 1100 DD Amsterdam, The Netherlands. m.a.middelkamphup@amc.uva.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17659004

Citation

Middelkamp-Hup, M A., et al. "Treatment of Vitiligo Vulgaris With Narrow-band UVB and Oral Polypodium Leucotomos Extract: a Randomized Double-blind Placebo-controlled Study." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 21, no. 7, 2007, pp. 942-50.
Middelkamp-Hup MA, Bos JD, Rius-Diaz F, et al. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2007;21(7):942-50.
Middelkamp-Hup, M. A., Bos, J. D., Rius-Diaz, F., Gonzalez, S., & Westerhof, W. (2007). Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. Journal of the European Academy of Dermatology and Venereology : JEADV, 21(7), 942-50.
Middelkamp-Hup MA, et al. Treatment of Vitiligo Vulgaris With Narrow-band UVB and Oral Polypodium Leucotomos Extract: a Randomized Double-blind Placebo-controlled Study. J Eur Acad Dermatol Venereol. 2007;21(7):942-50. PubMed PMID: 17659004.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. AU - Middelkamp-Hup,M A, AU - Bos,J D, AU - Rius-Diaz,F, AU - Gonzalez,S, AU - Westerhof,W, PY - 2007/7/31/pubmed PY - 2007/11/9/medline PY - 2007/7/31/entrez SP - 942 EP - 50 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 21 IS - 7 N2 - BACKGROUND: The first choice treatment for vitiligo vulgaris is narrow-band UVB (NB-UVB), but no satisfactory treatment exists. OBJECTIVES: To investigate if Polypodium leucotomos, an antioxidative and immunomodulatory plant extract, improves NB-UVB-induced repigmentation. METHODS: Fifty patients with vitiligo vulgaris randomly received 250 mg oral P. leucotomos or placebo three times daily, combined with NB-UVB twice weekly for 25-26 weeks. RESULTS: Repigmentation was higher in the P. leucotomos group vs. placebo in the head and neck area (44% vs. 27%, P = 0.06). Small repigmentation increases (P = n.s.) were observed for the trunk (6% increased repigmentation), extremities (4%), and hands and feet (5%) in the P. leucotomos group vs. placebo. Patients attending more than 80% of required NB-UVB sessions showed increased repigmentation in the head and neck area in the P. leucotomos group vs. placebo (50% vs. 19%, P < 0.002); no significant differences were seen in the other body areas. Patients with skin types 2 and 3 showed more repigmentation in the head and neck area in the P. leucotomos group vs. placebo (47% vs. 21%, P = 0.01), and no significant differences were seen in the other body areas. No conclusions could be drawn on skin types 4 and 5 due to low patient numbers. CONCLUSION: There is a clear trend towards an increase in repigmentation of vitiligo vulgaris affecting the head and neck area when NB-UVB phototherapy is combined with oral P. leucotomos. This effect may be more pronounced in light skin types. SN - 0926-9959 UR - https://www.unboundmedicine.com/medline/citation/17659004/Treatment_of_vitiligo_vulgaris_with_narrow_band_UVB_and_oral_Polypodium_leucotomos_extract:_a_randomized_double_blind_placebo_controlled_study_ L2 - https://doi.org/10.1111/j.1468-3083.2006.02132.x DB - PRIME DP - Unbound Medicine ER -